Gapping up
In reaction to earnings/guidance:
- KMX +3.6%
Other news:
- KRMD +9.8% (receives FDA 510k clearance expanding on-label use to two additional SCIg drugs)
- VOYA +7.5% (to join S&P MidCap 400)
- KKR +5.3% (provides update on intra-quarter monetization activity for Q4)
- MX +4.3% (approves $75 mln share repurchase program)
- MREO +4.2% (and UAB Announce Positive Top-line Results from "COSTA" a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease)
- TSLA +3.7% (Musk was interviewed and said he has "sold enough stock" and was critical of California's high taxes)
- THO +2.3% (approves $250 mln share repurchase program)
- ELMS +2% (Glovis America orders from ELMS Urban Delivery to support its industrial operations)
- NVAX +1% (WHO SAGE gives interim recommendations for its COVID-19 vaccine; also announces initiation of PREVENT-19 study of booster doses of NVX-CoV2373),
Analyst comments:
- LOCL +6.5% (initiated with an Outperform at Oppenheimer)
- BIGC +2.6% (upgraded to Outperform from Neutral at Wedbush)
- LC +2.3% (assumed with an Outperform at Wedbush)
- LAZR +1.9% (resumed with a Buy at Citi)
- DRI +1.8% (upgraded to Buy from Hold at Stifel)
- CAT +1.7% (upgraded to Outperform from Mkt Perform at Bernstein)
- ARAY +1.7% (initiated with a Buy at Loop),